



Prior Authorization Approval Criteria

Mirapex ER (pramipexole)

Generic name:	pramipexole
Brand name:	Mirapex ER
Medication class:	antiparkinsons agent
FDA-approved uses:	For the treatment of the signs and symptoms of Parkinson's disease.
Available dosage forms:	0.375mg, 0.75mg, 1.5mg, 3mg, and 4.5mg extended release tablets
Usual dose:	0.375mg-4.5mg once daily
Approximate monthly cost: (based on AWP 2010)	\$295.00/month
Duration of therapy:	Indefinite

Criteria for use (*bullet points below are all inclusive unless otherwise noted*):

- The indicated diagnosis (including any applicable labs and /or tests) and medication usage must be supported by documentation from the patient's medical records.
 - Must be clinically diagnosed with Parkinson's disease
 - Must be intolerant to immediate release generic pramipexole.
- Or
- Must have tried and failed immediate release generic pramipexole.

Contraindication:

- None listed at this time.

Not approved if:

- Patient does not meet the above stated criteria

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 12/08/10